Join
Neoleukin Therapeutics Inc. logo

NLTX

NASDAQ

Neoleukin Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2014
$13.96+10.46 (+298.86%)
News25/Ratings2

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Latest news

25 items

NLTX FAQ

7 questions
  • What does Neoleukin Therapeutics Inc. do?
    Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and...
  • Where does NLTX stock trade?
    Neoleukin Therapeutics Inc. (NLTX) is listed on NASDAQ.
  • What sector and industry is NLTX in?
    Neoleukin Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Neoleukin Therapeutics Inc. go public?
    Neoleukin Therapeutics Inc. (NLTX) completed its IPO in 2014.
  • What are analysts saying about NLTX?
    Neoleukin Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $2500.00 price target on 2022-03-02. Recent price targets range from $2500.00 to $3000.00.
  • What companies are similar to NLTX?
    Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NLTX side-by-side with any of them on Quantisnow.
  • How can I track NLTX on Quantisnow?
    Quantisnow aggregates Neoleukin Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NLTX to receive live email and push alerts on every new disclosure.